@article{7edd7faca09c4f84acec9c3d0aec8352,
title = "Sphingolipids in Alzheimer's disease, how can we target them?",
keywords = "Ceramide, Sphingosine-1-phosphate (S1P), Sphingomyelin (SM), Alzheimer's disease, Blood brain barrier (BBB), GW4869, Tricyclic dibenzoazepines (TCA), Fingolimod (FTY720), AMYLOID PRECURSOR PROTEIN, NERVE GROWTH-FACTOR, KINASE-C-ZETA, BLOOD-BRAIN-BARRIER, CERAMIDE SYNTHASE 2, SERINE PALMITOYLTRANSFERASE INHIBITOR, MITOCHONDRIAL OUTER-MEMBRANE, CULTURED HIPPOCAMPAL-NEURONS, P75 NEUROTROPHIN RECEPTOR, ANTIGEN-BINDING PROTEIN",
author = "Crivelli, {Simone M.} and Caterina Giovagnoni and Lars Visseren and Anna-Lena Scheithauer and {de Wit}, Nienke and {den Hoedt}, Sandra and Mario Losen and Mulder, {Monique T.} and Jochen Walter and {de Vries}, {Helga E.} and Erhard Bieberich and Pilar Martinez-Martinez",
year = "2020",
doi = "10.1016/j.addr.2019.12.003",
language = "English",
volume = "159",
pages = "214--231",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier Science",
}